Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% (Sterile) | Cyclopentolate Hydrochloride

19:02 EST 21st November 2014 | BioPortfolio
Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Rx only

Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% is an anticholinergic prepared as a sterile, borate buffered, solution for topical ocular use. The active ingredient is represented by the following structural formula:

CHNO • HClMol. Wt. 327.85

Chemical name: 2-(Dimethylamino) ethyl 1-hydroxy-α-phenylcyclopentaneacetate hydrochloride.

Each mL Contains:

ACTIVE: Cyclopentolate Hydrochloride, 10 mg (1%)

INACTIVES: Boric Acid, Potassium Chloride, Edetate Disodium, Purified Water. Sodium Carbonate and/or Hydrochloric Acid may be added to adjust pH (3.0-5.5).

PRESERVATIVE ADDED: Benzalkonium Chloride 0.01%.

IMAGE 4d4131f8-79d0-40a4-87e8-667fd2db8d7a-01.jpg

This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days.

Cyclopentolate Hydrochloride Ophthalmic Solution is used to produce mydriasis and cycloplegia in diagnostic procedures.

Should not be used when narrow-angle glaucoma or anatomical narrow angles are present, or where there is hypersensitivity to any component of this preparation.

For Topical Use Only - Not For Injection. This preparation may cause CNS disturbances. This is especially true in younger age groups, but may occur at any age, especially with the stronger cyclopentolate hydrochloride solution. Premature and small infants are especially prone to CNS and cardiopulmonary side effects from systemic absorption of cyclopentolate. To minimize absorption, use only 1 drop of a 0.5% solution per eye followed by pressure applied over the nasolacrimal sac for two to three minutes. Observe infants closely for at least 30 minutes following instillation.

To avoid inducing angle closure glaucoma, an estimation of the depth of the angle of the anterior chamber should be made. The lacrimal sac should be compressed by digital pressure for two to three minutes after instillation to avoid excessive systemic absorption. Caution should be observed when considering use of this medication in the presence of Down’s syndrome or mongolism, and in those predisposed to angle-closure glaucoma.

Do not touch dropper tip to any surface as this may contaminate the solution. A transient burning sensation may occur upon instillation. Patients should be advised not to drive or engage in other hazardous activities while pupils are dilated. Patients may experience sensitivity to light and should protect eyes in bright illumination during dilation. Parents should be warned not to get this preparation in their child’s mouth and to wash their own hands and the child’s hands following administration.

Cyclopentolate may interfere with the antiglaucoma action of carbachol or pilocarpine; also, concurrent use of these medications may antagonize the anti-glaucoma and miotic actions of ophthalmic cholinesterase inhibitors.

Studies in animals or humans have not been conducted to evaluate the potential of these effects.

Animal reproduction studies have not been conducted with cyclopentolate. It is also not known whether cyclopentolate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cyclopentolate should be administered to a pregnant woman only if clearly needed.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when cyclopentolate hydrochloride is administered to a nursing woman.

Increased susceptibility to cyclopentolate has been reported in pediatric patients with spastic paralysis or brain damage. Therefore, cyclopentolate should be used with great caution in these patients. Feeding intolerance may follow ophthalmic use of this product in neonates. It is recommended that feeding be withheld for four (4) hours after examination. Do not use concentrations higher than 0.5% in small infants (see WARNINGS ).

In the elderly and others where increased intraocular pressure may be encountered, mydriatics and cycloplegics should be used cautiously.

Ocular: Increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae.

Systemic: Use of cyclopentolate has been associated with psychotic reactions and behavioral disturbances, usually in pediatric patients, especially with a 2% concentration. These disturbances include ataxia, incoherent speech, restlessness, hallucinations, hyperactivity, seizures, disorientation as to time and place, and failure to recognize people. This drug produces reactions similar to those of other anticholinergic drugs, but the central nervous system manifestations as noted above are more common. Other toxic manifestations of anticholinergic drugs are skin rash, abdominal distention in infants, unusual drowsiness, tachycardia, hyperpyrexia, vasodilation, urinary retention, diminished gastrointestinal motility and decreased secretion in salivary and sweat glands, pharynx, bronchi and nasal passages. Severe manifestations of toxicity include coma, medullary paralysis and death.

Excessive dosage may produce exaggerated symptoms as noted in ADVERSE REACTIONS . When administration of the drug product is discontinued, the patient usually recovers spontaneously. In case of severe manifestations of toxicity the antidote of choice is physostigmine salicylate.

Pediatric Dose: As an antidote, slowly inject intravenously 0.5 mg physostigmine salicylate. If toxic symptoms persist and no cholinergic symptoms are produced repeat at five minute intervals to a maximum cumulative dose of 2 mg.

Adolescent and Adult: As an antidote, slowly inject 2 mg physostigmine salicylate intravenously. A second dose of 1 to 2 mg may be given after 20 minutes if no reversal of toxic manifestations has occurred.

Adults: One or two drops of 0.5%, 1% or 2% solution in the eye, which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours.

Pediatric Patients: One or two drops of 0.5%, 1% or 2% solution in the eye, which may be repeated five to ten minutes later by a second application of 0.5% or 1% solution if necessary.

Small Infants: A single instillation of one drop of 0.5% solution in the eye. To minimize absorption, apply pressure over the nasolacrimal sac for two to three minutes. Observe infant closely for at least 30 minutes following instillation.

Individuals with heavily pigmented irises may require higher strengths.

Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% is available in multidose plastic squeeze bottles with a controlled drop tip and red cap in the following sizes:

15 mL bottle - NDC 42254-013-15

Store between 15°-30°C (59°-86°F).

FOR OPHTHALMIC USE ONLY

DO NOT USE IF IMPRINTED NECKBAND IS NOT INTACT.

KEEP OUT OF REACH OF CHILDREN.

1. Rumack, B.H.: Anticholinergic Poisoning: Treatment with Physostigmine. Pediatrics 52(6): 449-51, 1973.

2. Duvoisin, R.C. and Katz, R.: Reversal of Central Anticholinergic Syndromes in Man by Physostigmine, J. Am. Med. Assn. 206(9): 1963-65,1968.

3. Grant, W.M.: Toxicology of the Eye. Second Edition, Volume 1. Springfield, Illinois, Charles C. Thomas: 1974.

Revised November 2007

Bausch & Lomb Incorporated

Tampa, FL 33637

©Bausch & Lomb Incorporated

Relabeled by:

Rebel Distributors Corp

Thousand Oaks, CA 91320

NDC 42254-013-15

Rebel Distributors Corp

Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% (Sterile)

Rx only

[icon- eye] [icon- 1%] [icon- solution] [icon- 15 mL]

IMAGE 4d4131f8-79d0-40a4-87e8-667fd2db8d7a-02.jpg

Manufacturer

Rebel Distributors Corp

Active Ingredients

Source

Drugs and Medications [573 Associated Drugs and Medications listed on BioPortfolio]

Cyclopentolate hydrochloride [Akorn, Inc.]

Cyclopentolate HydrochlorideOphthalmic Solution, USP –Sterile

Ak-pentolate [Rebel Distributors Corp.]

AK-PENTOLATE™ Cyclopentolate Hydrochloride Ophthalmic Solution, USP -Sterile

Cyclomydril [Alcon Laboratories, Inc.]

Cyclomydril (cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution) Sterile

Cyclopentolate hydrochloride [Falcon Pharmaceuticals, Ltd.]

Cyclopentolate Hydrochloride Ophthalmic Solution USP

Cyclopentolate hydrochloride [Bausch & Lomb Incorporated]

Cyclopentolate Hydrochloride Ophthalmic Solution USP, 1% (Sterile)

Clinical Trials [1061 Associated Clinical Trials listed on BioPortfolio]

Study on Effective Mydriasis in Premature Infants

The purpose of this study is to compare the dilating effect of 0, 1, 2 or 3 drops of mydriatic (pupil dilating) in premature infants undergoing routine retinal (eye) screening exams for Re...

Does Undercorrection of Myopia Retard Myopia Progression Among Kindergarten Children?

The purpose of this study is to find out if undercorrection of myopia slow down the progression of myopia in kindergarten children.

Double-blind Comparative Study of SYR-322-MET.

To evaluate the safety and efficacy of treatment with metformin hydrochloride in diabetic patients when used in combination with SYR-322.

Dexmethylphenidate Hydrochloride Tablets Under Fasting Conditions

The objective of this randomized, single-dose, two-way evaluation is to compare the bioequivalence of a test dexmethylphenidate hydrochloride formulation to an equivalent oral dose of the ...

First Time in Man Study of Finafloxacin Hydrochloride

The purpose of this study is to study the safety of single doses and multiple doses of Finafloxacin hydrochloride in healthy volunteers. The level of Finafloxacin hydrochloride will be mea...

PubMed Articles [198 Associated PubMed Articles listed on BioPortfolio]

Influences of Topical Cyclopentolate on Anterior Chamber Parameters With a Dual-Scheimpflug Analyzer in Healthy Children.

To evaluate the changes of anterior segment parameters following the topical instillation of cyclopentolate hydrochloride 1% with the Galilei dual-Scheimpflug analyzer (GSA) (Ziemer Ophthalmology Co.,...

Acute Psychotic Symptoms due to Benzydamine Hydrochloride Abuse with Alcohol.

Benzydamine hydrochloride is a locally acting nonsteroidal anti-inflammatory drug. Benzydamine hydrochloride overdose can cause stimulation of central nervous system, hallucinations, and psychosis. We...

The Mydriaticum Cyclopentolate Induces Severe Allergy in a 5-year-old Child.

Development and validation of an HPLC method for tetracycline-related USP monographs.

A novel reversed-phase HPLC method was developed and validated for the assay of tetracycline hydrochloride and the limit of 4-epianhydrotetracycline hydrochloride impurity in tetracycline hydrochlorid...

New Thermoresistant Polymorph from CO2 Recrystallization of Minocycline Hydrochloride.

To prepare and thoroughly characterize a new polymorph of the broad-spectrum antibiotic minocycline from its hydrochloride dehydrate salts.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Rheumatology
Latest News Clinical Trials Research Drugs Reports Corporate
Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Dictionary). It is an active area of medical research, because of the d...

Advertisement

Drugs and Medication Quicklinks


Searches Linking to this Drug Record